We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2019 to May 2024
Dr. Narasimhan, a U.S. citizen of Indian descent, joined Novartis in 2005 from consultancy McKinsey & Co., and rose quickly through the Swiss drugmaker's ranks to become chief medical officer and global head of drug development. "Novartis CEO Steers Drug Maker Back to R&D," at 09:02 GMT, incorrectly said Dr. Narasimhan is a U.S. citizen of Indian descent. A previous version of this story incorrectly said he was born in India. Dr. Narasimhan was Novartis' chief medical officer and global head of drug development. The earlier version of the story incorrectly said he was head of the company's research and development.
(END) Dow Jones Newswires
February 19, 2018 07:16 ET (12:16 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
